October 27, 2014

Canton, MI—MedTest Holdings (“MedTest”), the parent company of MedTest DX and Pointe Scientific, has signed a definitive agreement to acquire Clinitox Diagnostix located in Mississauga, Ontario, Canada.  MedTest is an in-vitro diagnostics company providing automated, fast and cost-effective blood and urine testing solutions for diabetes, cardiovascular disease, urine drugs of abuse screening and wellness testing.

Clinitox Diagnostix was founded in 2010 by Howard Lee.  Clinitox Diagnostix provides drugs of abuse confirmatory testing capabilities via liquid chromatography/mass spectrophotometry (LC/MS) instrumentation and associated reagents and consumables as pre-packaged kits.  Implementation consulting provides the customer with on-site assistance in setting up their LC/MS testing and developing the standard operating procedures enabling the laboratory to initiate testing sooner and reduce costly start-up costs.

Hanjoon Ryu, CEO of MedTest, stated:  “The addition of Clinitox Diagnostix to our portfolio enables us to become a highly differentiated provider of extensive solutions in the drugs of abuse testing market.  Now we can provide the laboratory with confirmatory drugs of abuse testing capability in addition to the urine drugs of abuse screening testing that can be performed on the Mindray™ BS-200 and BS-480 Chemistry Analyzers.  Our clinical expertise in the drugs of abuse testing market meets both individual laboratory testing needs as well as the needs of the growing hub-and-spoke regional toxicology networks.”

In addition to manufacturing and distribution of reagents, calibrators and quality control products for the general chemistry and drugs of abuse testing markets, MedTest is the exclusive US distributor of the Mindray™ floor model BS-480 Chemistry Analyzer and the bench-top BS-200 Chemistry Analyzer.  The acquisition of Clinitox enables MedTest to provide a more integrated service offering of innovative instruments with proven quality reagents, superior customer support and recognized economic advantages.